Lipid lowering efficacy of rosuvastatin

  • Protocol
  • Intervention

Authors

  • Stephen P Adams,

    1. University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, Canada
    Search for more papers by this author
  • James M Wright

    Corresponding author
    1. University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, Canada
    • James M Wright, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Medical Block C, Vancouver, V6T 1Z3, Canada. jim.wright@ti.ubc.ca.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objective

To quantify the effects of various doses of rosuvastatin on serum total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in subjects with and without evidence of cardiovascular disease. The primary focus of the review will be on the mean per cent change of LDL-cholesterol.

Secondary objective

To quantify the variability of the effect of various doses of rosuvastatin.

To quantify withdrawals due to adverse effects in the randomized placebo controlled trials. 

Ancillary